JP6149906B2 - 動物に給餌するための生成物、および、動物に給餌するための生成物の製造工程 - Google Patents
動物に給餌するための生成物、および、動物に給餌するための生成物の製造工程 Download PDFInfo
- Publication number
- JP6149906B2 JP6149906B2 JP2015176835A JP2015176835A JP6149906B2 JP 6149906 B2 JP6149906 B2 JP 6149906B2 JP 2015176835 A JP2015176835 A JP 2015176835A JP 2015176835 A JP2015176835 A JP 2015176835A JP 6149906 B2 JP6149906 B2 JP 6149906B2
- Authority
- JP
- Japan
- Prior art keywords
- feeding
- chow
- therapeutic
- solid feed
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001465754 Metazoa Species 0.000 title claims description 52
- 238000000034 method Methods 0.000 title claims description 28
- 230000008569 process Effects 0.000 title claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 50
- 239000007787 solid Substances 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 40
- 239000004480 active ingredient Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 20
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 210000000845 cartilage Anatomy 0.000 claims description 10
- 235000009467 Carica papaya Nutrition 0.000 claims description 9
- 235000019789 appetite Nutrition 0.000 claims description 9
- 230000036528 appetite Effects 0.000 claims description 9
- 238000001125 extrusion Methods 0.000 claims description 9
- 241000251730 Chondrichthyes Species 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 240000008886 Ceratonia siliqua Species 0.000 claims description 6
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 6
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 6
- 235000013312 flour Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 235000021283 resveratrol Nutrition 0.000 claims description 6
- 229940016667 resveratrol Drugs 0.000 claims description 6
- 241000241413 Propolis Species 0.000 claims description 5
- 235000011399 aloe vera Nutrition 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229940069949 propolis Drugs 0.000 claims description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- 241001116389 Aloe Species 0.000 claims description 4
- 244000099147 Ananas comosus Species 0.000 claims description 4
- 235000007119 Ananas comosus Nutrition 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 240000002657 Thymus vulgaris Species 0.000 claims description 4
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000001585 thymus vulgaris Substances 0.000 claims description 4
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 3
- 240000006432 Carica papaya Species 0.000 claims description 3
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 240000008530 Rosa canina Species 0.000 claims description 3
- 235000000539 Rosa canina Nutrition 0.000 claims description 3
- 235000013793 astaxanthin Nutrition 0.000 claims description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 3
- 229940022405 astaxanthin Drugs 0.000 claims description 3
- 239000001168 astaxanthin Substances 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 235000017276 Salvia Nutrition 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 239000011812 mixed powder Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000219173 Carica Species 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 229940093797 bioflavonoids Drugs 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- -1 bioflavonoids Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020429 malt syrup Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012260 resinous material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/20—Shaping or working-up of animal feeding-stuffs by moulding, e.g. making cakes or briquettes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Feed For Specific Animals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
特許文献4は、コーンスターチ及びステアリン酸マグネシウムを含む、獣医が投与する大型丸薬について開示している。この大型丸薬は直接圧縮により調合され、乳糖も含む。この大型丸薬は動物用飼料または飲料水へも添加される。
本発明の別の目的は、医薬品、サプリメント、植物療法物質、及び一般に治療目的の有効成分を含んでいても動物にとっておいしい治療目的の固形飼料を含む動物給餌用生成品を提供することである。
Claims (7)
- 動物に給餌するための生成物であって、
包装、および、外側が脂肪性食欲促進物質でコーティング又は噴霧され、前記包装に包含された給餌目的の固形飼料を含むこと;
前記包装内に包含され、大量の前記給餌目的の固形飼料内に、均一に混合された治療目的の固形飼料が、5〜15%の割合で含まれており、前記治療目的の固形飼料は、乾式プレスにより固形飼料の形態に圧密化された粉末状成分の混合物中に、6%未満の湿分を含むこと;
前記粉末状成分の混合物が、冷温及び乾式プレスにより前記成分を一緒に圧密化するための少なくとも1種類の増粘剤と、前記治療目的の固形飼料から前記湿分を吸収し、前記プレスからの固形飼料の形態に圧密化された前記混合物の分離を促進するための少なくとも1種類の親水性無機物と、熱に弱い又は酸化されやすい有効成分を含む、動物を治療するための少なくとも1種類の治療物質と、を含むこと;
前記給餌目的の固形飼料が有する脂肪性食欲促進物質の一部が前記治療目的の固形飼料表面へ移り、前記治療目的の固形飼料をも極めておいしくするために、前記治療目的の固形飼料と前記給餌目的の固形飼料との単純接触により、前記治療目的の固形飼料が前記脂肪性食欲促進物質を吸収すること;及び
前記給餌目的の固形飼料中で前記治療目的の固形飼料を均一に分布させるために、前記治療目的の固形飼料の密度が前記給餌目的の固形飼料の密度と同様であること;
を特徴とする、動物に給餌するための生成物。 - 前記治療物質が、ビタミンC、リゾチーム、バイオフラボノイド、サメの軟骨、コンドロイチン、グルコサミン、プロポリス、エキナシア、アスタキサンチン、パパイヤ、アロエ、朝鮮人参、パイナップル、ロサ・カニナ、パパイヤ、レスベラトロール、カルニチン、サルビア、タイム及びプロポリスからなる群の中から、単独又は組み合わせて選択される、請求項1に記載の動物に給餌するための生成物。
- 前記増粘剤の中に、イナゴマメ粉が含まれている、請求項1に記載の動物に給餌するための生成物。
- 前記増粘剤の中に、二リン酸カルシウム、トウモロコシ澱粉、マルトデキストリンの中の1種類又は複数の成分が含まれる、請求項1に記載の動物に給餌するための生成物。
- 前記親水性無機物の中に、ステアリン酸マグネシウム又はシリカが含まれる、請求項1に記載の動物に給餌するための生成物。
- 治療目的の固形飼料を、外側に脂肪がコーティングされた又は食欲促進物質が噴霧された給餌目的の固形飼料と混合し;
給餌目的の固形飼料が押出法を利用して得られ;
前記押出法によって得られた給餌目的の固形飼料に、動物または植物由来の脂肪性食欲促進物質がコーティング又は噴霧され;
治療目的の固形飼料が次の(a)ないし(b)の操作ステップによって得られ:
(a)粉末状の少なくとも1種類の増粘成分と、粉末状の少なくとも1種類の親水性無機物と、動物を治療するための、熱に弱い又は酸化されやすい有効成分を含む粉末状の少なくとも1種類の治療物質とを均一に混合するステップ
(b)前記混合粉末を乾式プレスし、固形飼料の形態で小型の凝塊を得るステップ;
前記治療目的の固形飼料が5〜15%の割合で含まれるように、前記給餌目的の固形飼料と混合される:
動物に給餌するための生成物の製造工程であって、
前記治療目的の固形飼料が、前記治療目的の固形飼料と給餌目的の固形飼料との混合ステップにおいて、前記給餌目的の固形飼料との単純接触によって、前記給餌目的の固形飼料表面の脂肪性食欲促進物質の一部を吸収すること;及び
前記給餌目的の固形飼料中で前記治療目的の固形飼料を均一に分布させるために、前記治療目的の固形飼料の密度が前記給餌目的の固形飼料の密度と同様であり、前記治療目的の固形飼料は、大量の前記給餌目的の固形飼料内に、均一に混合されること;
を特徴とする動物に給餌するための生成物の製造工程。 - 前記給餌目的の固形飼料は、押出チャンバーへ導入され、少なくとも1つのウオームスクリューの作用を利用して、押出機の上部に配列される金型の穴を通過する成分の混合物から開始する押出法により得られ、前記金型から出る混合物は、ブレードにより任意の固形飼料の形態に切断される、請求項6に記載の動物用生成品の製造工程。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITPD2007A000274 | 2007-08-08 | ||
IT000274A ITPD20070274A1 (it) | 2007-08-08 | 2007-08-08 | Crocchetta per animali e metodo per la sua produzione |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010519541A Division JP2010535493A (ja) | 2007-08-08 | 2008-08-04 | 動物給餌用生成品及び動物用生成品の製造工程 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016027810A JP2016027810A (ja) | 2016-02-25 |
JP6149906B2 true JP6149906B2 (ja) | 2017-06-21 |
Family
ID=40091491
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010519541A Pending JP2010535493A (ja) | 2007-08-08 | 2008-08-04 | 動物給餌用生成品及び動物用生成品の製造工程 |
JP2015176835A Active JP6149906B2 (ja) | 2007-08-08 | 2015-09-08 | 動物に給餌するための生成物、および、動物に給餌するための生成物の製造工程 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010519541A Pending JP2010535493A (ja) | 2007-08-08 | 2008-08-04 | 動物給餌用生成品及び動物用生成品の製造工程 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100209572A1 (ja) |
EP (1) | EP2185129B1 (ja) |
JP (2) | JP2010535493A (ja) |
BR (1) | BRPI0815609A2 (ja) |
IT (1) | ITPD20070274A1 (ja) |
RU (1) | RU2469549C2 (ja) |
WO (1) | WO2009019593A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110027417A1 (en) | 2009-07-31 | 2011-02-03 | Patrick Joseph Corrigan | Process for Dusting Animal Food |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
FR2973705B1 (fr) * | 2011-04-06 | 2013-08-02 | Esprit D Ethique | Inhibiteur de tnf-alpha. |
ITPD20110176A1 (it) | 2011-05-27 | 2012-11-28 | Sanypet Spa | Prodotto per l'alimentazione di animali |
CN102552754B (zh) * | 2012-02-23 | 2014-03-19 | 青岛绿曼生物工程有限公司 | 促进肉禽生长育肥的复方蜂胶组合物及其制备方法 |
US20140030382A1 (en) * | 2012-07-25 | 2014-01-30 | Robbert H. ter Haar | Bacteriophage Treated Food Products |
CN103432082A (zh) * | 2013-08-29 | 2013-12-11 | 江苏正大清江制药有限公司 | 氨基葡萄糖组合物及其制备方法 |
EP2893934B1 (en) | 2014-01-09 | 2018-10-03 | Sanypet S.p.a. | Product for feeding dogs in order to protect them from leishmaniasis |
MX2017013715A (es) | 2015-04-28 | 2018-03-02 | Mars Inc | Proceso de preparacion de un producto de alimento para mascotas humedo esterilizado. |
JP2017075136A (ja) * | 2015-06-08 | 2017-04-20 | ロート製薬株式会社 | 内服組成物 |
BR112021004519A2 (pt) * | 2018-09-11 | 2021-06-08 | Dsm Ip Assets B.V. | composição de ração animal e uso da mesma |
US20220040271A1 (en) * | 2018-09-17 | 2022-02-10 | Dsm Ip Assets B.V. | Animal feed compositions and uses thereof |
RU2724531C1 (ru) * | 2020-03-11 | 2020-06-23 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кузбасская государственная сельскохозяйственная академия" | Способ получения сухого экстракта эхинацеи пурпурной для сельскохозяйственных животных и птицы (варианты) |
JP7296675B1 (ja) * | 2022-11-15 | 2023-06-23 | 株式会社日本食品薬化 | 食品組成物 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3014800A (en) * | 1958-04-10 | 1961-12-26 | Cargill Inc | Manufacture of a hard, dry fat containing feed pellet |
GB1050767A (ja) * | 1963-08-14 | |||
CA978414A (en) * | 1970-02-25 | 1975-11-25 | Ralston Purina Company | Intermediate moisture food product |
DE2362539C2 (de) * | 1973-12-17 | 1986-05-07 | Merck Patent Gmbh, 6100 Darmstadt | 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
FR2313079A2 (fr) * | 1975-06-02 | 1976-12-31 | Sucrest Corp | Vehicules a compression directe pour la fabrication de comprimes |
FR2476485A1 (fr) * | 1980-02-26 | 1981-08-28 | Roussel Uclaf | Nouveau procede d'enrobage d'au moins un principe actif medicamenteux, les nouveaux medicaments ainsi obtenus, et les compositions les renfermant |
US4443109A (en) * | 1981-09-21 | 1984-04-17 | Vol-Pro Systems, Inc. | Method and apparatus for continuous feeding, mixing and blending |
US4495177A (en) * | 1983-01-17 | 1985-01-22 | Shaklee Corporation | Gel tableting agent |
GB8333835D0 (en) | 1983-12-20 | 1984-02-01 | Beecham Group Plc | Compounds |
AU621282B2 (en) * | 1986-12-18 | 1992-03-12 | Alpharma (Luxembourg) S.A.R.L. | Stable antibiotic ester feed compositions |
US4857332A (en) * | 1988-05-31 | 1989-08-15 | Pitman-Moore, Inc. | Composition and method for increasing milk fat production in ruminants |
JP2941163B2 (ja) * | 1993-02-19 | 1999-08-25 | 武田薬品工業株式会社 | ペットの尿結石症治療・予防剤および治療方法 |
NZ302661A (en) * | 1995-02-24 | 1999-10-28 | Novartis Ag | Composition for controlling parasites comprising n phenyl-n'-benzoylurea derivatives |
US5540932A (en) * | 1995-04-13 | 1996-07-30 | Purina Mills, Inc. | Extruded animal feed nuggets for ruminants |
NL1003855C1 (nl) * | 1996-05-29 | 1997-12-03 | Confedera B V | Vitamine C-samenstelling met vruchtensmaak en werkwijze voor het bereiden van vitamine C-tabletten. |
US6117477A (en) | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
EP0951902A1 (en) * | 1998-03-31 | 1999-10-27 | Edmund J.H. Campion | A feed mixture |
US6403142B1 (en) * | 1998-12-11 | 2002-06-11 | Ralston Purina Company | Hypoallergenic pet food |
US6506401B1 (en) | 1999-01-28 | 2003-01-14 | H. J. Heinz Company | Filled edible product, and system and method for production of a filled edible product |
DE19940944B4 (de) * | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retardierte, orale, pharmazeutische Darreichungsformen |
US6358526B1 (en) * | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
US9107804B2 (en) * | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
US20080280274A1 (en) * | 2005-06-01 | 2008-11-13 | Kim Gene Friesen | Methods For Enhancing Palatability of Compositions for Animal Consumption |
RU2283114C1 (ru) * | 2005-06-07 | 2006-09-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы |
CA2623214C (en) * | 2005-09-30 | 2011-07-26 | Hill's Pet Nutrition, Inc. | Methods for extending the shelf-life of food compositions containing polyunsaturated fatty acids |
ATE476176T1 (de) * | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
-
2007
- 2007-08-08 IT IT000274A patent/ITPD20070274A1/it unknown
-
2008
- 2008-08-04 WO PCT/IB2008/002107 patent/WO2009019593A1/en active Application Filing
- 2008-08-04 RU RU2010108225/13A patent/RU2469549C2/ru active
- 2008-08-04 JP JP2010519541A patent/JP2010535493A/ja active Pending
- 2008-08-04 EP EP08789057.0A patent/EP2185129B1/en not_active Not-in-force
- 2008-08-04 BR BRPI0815609 patent/BRPI0815609A2/pt not_active Application Discontinuation
-
2010
- 2010-02-12 US US12/705,363 patent/US20100209572A1/en not_active Abandoned
-
2015
- 2015-09-08 JP JP2015176835A patent/JP6149906B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009019593A1 (en) | 2009-02-12 |
EP2185129A1 (en) | 2010-05-19 |
JP2010535493A (ja) | 2010-11-25 |
BRPI0815609A2 (pt) | 2015-03-24 |
EP2185129B1 (en) | 2015-10-21 |
JP2016027810A (ja) | 2016-02-25 |
RU2010108225A (ru) | 2011-09-20 |
US20100209572A1 (en) | 2010-08-19 |
RU2469549C2 (ru) | 2012-12-20 |
ITPD20070274A1 (it) | 2009-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6149906B2 (ja) | 動物に給餌するための生成物、および、動物に給餌するための生成物の製造工程 | |
KR102117357B1 (ko) | 애견용 한방 종합 영양 간식 조성물 | |
KR101674572B1 (ko) | 피모건강에 효과적인 반려동물 간식 및 간식 제조방법 | |
JP2003508069A (ja) | ペットフード製品およびそれを製造する方法 | |
NZ514389A (en) | Pet food containing an extract of perna canaliculus (NZ green lipped mussel) for maintenance of joint health and alleviation of arthritic symptoms in companion animals | |
CN111202164B (zh) | 一种宠物驱虫复合软胶囊及其制备方法 | |
CN110432482A (zh) | 一种小儿过敏性皮炎专用型临床营养配方及其制备方法 | |
CN104783003A (zh) | 用于小猪的中草药全价饲料及其制备方法 | |
US6428817B1 (en) | Companion animal therapeutic treat | |
CA2336602C (en) | Companion animal therapeutic treat | |
US9474292B1 (en) | Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals | |
CN108541912A (zh) | 一种抗氧化降血脂组合物及其制备方法和应用 | |
US11357802B2 (en) | Oral delivery compositions for improved gut barrier protection and immunity in mammals | |
EP2526781B1 (en) | Product for feeding animals | |
KR20180126691A (ko) | 관절염용 환제 및 그 제조방법 | |
WO2021074807A1 (en) | Nutritional supplement | |
KR20040046570A (ko) | 양파 및 마늘을 이용한 분말청국장의 제조방법 | |
KR100639294B1 (ko) | 양계용 천연광석물조성물과 이를 이용한 양계용 건강기능성보조사료 및 그 제조방법 | |
JP2005255574A (ja) | IgA産生恒常化剤及びそれを含有するストレス性疾患予防用及び/又は治療用組成物 | |
KR20150066440A (ko) | 설사 예방 및 개선용 조성물 및 이를 이용한 경구용 주사기 패키지 | |
Abd El Latif | EVALUATION OF FEED ADDITIVES SUPPLEMENTATION ON GROWTH MEASUREMENTS, DIGESTIBILITY, BLOOD METABOLITES AND ECONOMICAL EFFECIENCY OF GROWING RABBITS | |
CN107494922A (zh) | 一种用于调节肠道的微生态中药饲料添加剂及其制备方法 | |
WO2006111542A1 (en) | Method for increasing the speed of recovery and/or the speed of wound healing of injured animals | |
CN106036087A (zh) | 全鱼粉猪用浓缩料及其制备方法 | |
JP2003171289A (ja) | 鎮痛用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161007 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170411 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6149906 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |